Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ola Landgren

Showing results (261-270 of 519) with videos related to

Pageof 52
Sort By:
Blood|February 3, 2009
Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in SwedenOla Landgren, Sigurdur Y Kristinsson, Lynn R Goldin, et al.
British Journal of Haematology|December 10, 2009
Temporal trends in the proportion cured among adults diagnosed with acute myeloid leukaemia in Sweden 1973-2001, a population-based studyTherese M-L Andersson, Paul C Lambert, Asa Rangert Derolf, et al.
Blood Cancer Journal|July 24, 2020
Baseline VDJ clonotype detection using a targeted sequencing NGS assay: allowing for subsequent MRD assessmentMalin Hultcrantz, Even Holth Rustad, Venkata Yellapantula, et al.
Blood Advances|May 10, 2023
Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR studySaad Z Usmani, Hang Quach, Maria-Victoria Mateos, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 11, 2005
Familial aggregation and heterogeneity of non-Hodgkin lymphoma in population-based samplesLynn R Goldin, Ola Landgren, Mary L McMaster, et al.
Plos One|November 16, 2013
Quantifying cancer absolute risk and cancer mortality in the presence of competing events after a myotonic dystrophy diagnosisShahinaz M Gadalla, Ruth M Pfeiffer, Sigurdur Y Kristinsson, et al.
Blood Advances|January 4, 2018
MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methodsMikhail Roshal, Juan A Flores-Montero, Qi Gao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 9, 2008
Survival patterns among lymphoma patients with a family history of lymphomaLesley A Anderson, Ruth M Pfeiffer, Joshua S Rapkin, et al.
Annals of Hematology|March 31, 2025
Correction to: Evolution of frontline treatment for multiple myeloma: clinical investigation of quadruplets containing carflzomib and antiCD38 monoclonal antibodiesLuciano J Costa, Francesca Gay, Ola Landgren, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 14, 2025
Health-Related Quality of Life in Patients With Relapsed/Refractory Multiple Myeloma Treated With Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone: An Analysis of Patient-Reported Outcomes From the Phase 3 CANDOR TrialKatja Weisel, Maria-Victoria Mateos, Ola Landgren, et al.
Pageof 52

Showing results (261-270 of 519) with videos related to

Sort By:
Pageof 52
Blood|February 3, 2009
Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in SwedenOla Landgren, Sigurdur Y Kristinsson, Lynn R Goldin, et al.
British Journal of Haematology|December 10, 2009
Temporal trends in the proportion cured among adults diagnosed with acute myeloid leukaemia in Sweden 1973-2001, a population-based studyTherese M-L Andersson, Paul C Lambert, Asa Rangert Derolf, et al.
Blood Cancer Journal|July 24, 2020
Baseline VDJ clonotype detection using a targeted sequencing NGS assay: allowing for subsequent MRD assessmentMalin Hultcrantz, Even Holth Rustad, Venkata Yellapantula, et al.
Blood Advances|May 10, 2023
Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR studySaad Z Usmani, Hang Quach, Maria-Victoria Mateos, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 11, 2005
Familial aggregation and heterogeneity of non-Hodgkin lymphoma in population-based samplesLynn R Goldin, Ola Landgren, Mary L McMaster, et al.
Plos One|November 16, 2013
Quantifying cancer absolute risk and cancer mortality in the presence of competing events after a myotonic dystrophy diagnosisShahinaz M Gadalla, Ruth M Pfeiffer, Sigurdur Y Kristinsson, et al.
Blood Advances|January 4, 2018
MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methodsMikhail Roshal, Juan A Flores-Montero, Qi Gao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 9, 2008
Survival patterns among lymphoma patients with a family history of lymphomaLesley A Anderson, Ruth M Pfeiffer, Joshua S Rapkin, et al.
Annals of Hematology|March 31, 2025
Correction to: Evolution of frontline treatment for multiple myeloma: clinical investigation of quadruplets containing carflzomib and antiCD38 monoclonal antibodiesLuciano J Costa, Francesca Gay, Ola Landgren, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 14, 2025
Health-Related Quality of Life in Patients With Relapsed/Refractory Multiple Myeloma Treated With Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone: An Analysis of Patient-Reported Outcomes From the Phase 3 CANDOR TrialKatja Weisel, Maria-Victoria Mateos, Ola Landgren, et al.
Pageof 52